OncUpdates

This account is verified. Learn more

@OncUpdates

Latest oncology insights for medical professionals and patients| Curating the latest in research, trials & treatment advances| Own Views| Not medical advice

Worldwide oncupdates.com Joined November 2024

755 Following 1K Followers 2.2K Posts

Latest posts 5

Pinned post

OncUpdates @OncUpdates 2d

⭐️Part 1:DeLLphi-305-Tarlatamab + Durvalumab Maintenance in Extensive-Stage #SCLC

🎙️ Lead investigator @sands_jacob discusses the phase 3 data from #ESMO26
🎯 mOS 21.1 vs 12.7 mo
✅ mPFS 7.4 vs 1.9 mo
🔑New SOC for 1L maintenance

#lcsm #OncTwitter #SCLC
oncupdates.com/video-podcasts…

oncupdates.com DeLLphi-305: Tarlatamab and Durvalumab Maintenance in Extensive-Stage SCLC - OncUpdates Tarlatamab plus durvalumab maintenance in extensive-stage SCLC demonstrated significant overall and progression-free survival benefits in the DeLLphi-305 trial. Lead investigator Jacob Sands, MD, of...

OncUpdates @OncUpdates 1d

Congrats @UGrewalMD on the NANETS Nichole Borchard Foundation Research Grant 👏 #NANETS2026 @NANETS1 @WinshipAtEmory

Nicholas Hornstein Verified account @GIMedOnc 1d

Congrats to @UGrewalMD on the NANETS Nichole Borchard Foundation Research Grant! Well deserved.

Getting to work with Udhay has been the opportunity of a lifetime. Our strengths are complementary in the best way (thank you for helping me not ragequit every time during the peer review process).

This man eats, breathes and sleeps NET. No wonder he's already rapidly rising in the NET world within his first couple years of attending-hood. Here’s to many more years working together.

@TheGutOncLab

View quoted post on X

OncUpdates @OncUpdates 3d

⭐️ Going to #SABCS26 🤔

🤩Join Us for the @OncBrothers #AIO event featuring @sdent_cardioonc @sdent_cardioonc @hoperugo @ErikaHamilton9 @PTarantinoMD @hmcarthur + Dr. Hurvitz!

🔗Register: bit.ly/aiosabcs26

#bcsm #OncTwitter #BreastCancer @SABCSSanAntonio @HemOncFellows

1:10

OncUpdates @OncUpdates 3d

⭐️Ep. 1: Second-Line Treatment Options in #MultipleMyeloma

🎙️@OncBrothers w/ @CohenAd_MMdoc @kansagraMD @SurbhiSidanaMD
👉 Cilta-cel approved in 2L based on CARTITUDE-4
👉 Real-world data show comparable outcomes to trial
#mmsm #CART #HemOnc #OncTwitter
oncupdates.com/video-podcasts…

oncupdates.com Second-Line Treatments in MM and CARTITUDE-4 Data - OncUpdates Drs. Cohen, Kansagra, and Sidana discuss the data supporting cilta-cel as a leading second-line treatment option for relapsed or refractory multiple myeloma.

OncUpdates @OncUpdates 4d

⭐️ #ESMO26 | #HERIZON-GEA-01: Updated OS

✅ Zani + chemo: mOS 22.9 vs 19.6 mo (HR 0.76) vs trastuzumab + chemo
✅ Diarrhea common but grade ≥3 reduced with mandatory prophylaxis

#GIOnc #HER2 #gicsm #OncTwitter #MedEd @sawyer_bawek

📖 Full summary 👇
oncupdates.com/article/esmo-2…

oncupdates.com ESMO 2026: HERIZON-GEA-01 in HER2-Positive GEA - OncUpdates Understand the clinical significance and key takeaways from the updated HERIZON-GEA-01 overall survival analysis presented at ESMO 2026.